[How come? What for? Why? Questions on the topic of "Botulinum toxin in urology"].
Schulte-Baukloh
H
H
Klinik für Urologie, St. Hedwig-Krankenhaus, Akademisches Lehrkrankenhaus der Charité, Universitätsmedizin Berlin, Grosse Hamburger Strasse 5-11, 10115 Berlin. H.Schulte-Baukloh@alexius.de
Knispel
H H
HH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000378:metabolism; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000276:immunology; D002648:Child; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D009500:Neutralization Tests; D050825:Synaptosomal-Associated Protein 25 / Q000378:metabolism; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects* / Q000473:pathology; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000473:pathology
D000906:Antibodies; C494208:SNAP25 protein, human; D050825:Synaptosomal-Associated Protein 25; D019274:Botulinum Toxins, Type A
Mov Disord. 2000 Sep;15(5):973-6
11009207
Eur Urol. 2004 Dec;46(6):784-91
15548448
Mov Disord. 2006 Oct;21(10):1737-41
16874756
Exp Neurol. 1997 Sep;147(1):96-102
9294406